Header Logo

Connection

SALIM VIRANI to Hydroxymethylglutaryl-CoA Reductase Inhibitors

Back to Details
This is a "connection" page, showing publications SALIM VIRANI has written about Hydroxymethylglutaryl-CoA Reductase Inhibitors.
SALIM VIRANI
Connection Strength
27.103
Hydroxymethylglutaryl-CoA Reductase Inhibitors
  1. Highlights of Cardiovascular Disease Prevention Studies Presented at the 2023 European Society of Cardiology Congress. Curr Atheroscler Rep. 2023 12; 25(12):965-978.
    View in: PubMed
    Score: 0.545
  2. Highlights of Cardiovascular Disease Prevention Studies Presented at the 2023 American College of Cardiology Conference. Curr Atheroscler Rep. 2023 06; 25(6):309-321.
    View in: PubMed
    Score: 0.524
  3. With Current Safety and Efficacy Data, Should Statins Be Made Available as Nonprescription Over-the-Counter Drugs? Curr Cardiol Rep. 2023 05; 25(5):423-430.
    View in: PubMed
    Score: 0.521
  4. Cluster Randomized Trial of a Personalized Clinical Decision Support Intervention to Improve Statin Prescribing in Patients With Atherosclerotic Cardiovascular Disease. Circulation. 2023 05 02; 147(18):1411-1413.
    View in: PubMed
    Score: 0.519
  5. The importance of low-density lipoprotein cholesterol measurement and control as performance measures: A joint Clinical Perspective from the National Lipid Association and the American Society for Preventive Cardiology. J Clin Lipidol. 2023 Mar-Apr; 17(2):208-218.
    View in: PubMed
    Score: 0.518
  6. What is really new in triglyceride guidelines? Curr Opin Endocrinol Diabetes Obes. 2023 04 01; 30(2):73-80.
    View in: PubMed
    Score: 0.516
  7. Highlights of Cardiovascular Disease Prevention Studies Presented at the 2022 American Heart Association Scientific Sessions. Curr Atheroscler Rep. 2023 01; 25(1):31-41.
    View in: PubMed
    Score: 0.513
  8. Statin Use and Risk of Diabetes by Subclinical Atherosclerosis Burden (from a Multi-Ethnic Study of Atherosclerosis Report). Am J Cardiol. 2022 12 01; 184:7-13.
    View in: PubMed
    Score: 0.504
  9. Comparing eligibility for statin therapy for primary prevention under 2022 USPSTF recommendations and the 2018 AHA/ACC/ multi-society guideline recommendations: From National Health and Nutrition Examination Survey. Prog Cardiovasc Dis. 2022 Nov-Dec; 75:78-82.
    View in: PubMed
    Score: 0.501
  10. Statins and Primary Atherosclerotic Cardiovascular Disease Prevention-What We Know, Where We Need to Go, and Why Are We Not There Already? JAMA Netw Open. 2022 08 01; 5(8):e2228538.
    View in: PubMed
    Score: 0.498
  11. National trends and disparities in statin use for ischemic heart disease from 2006 to 2018: Insights from National Ambulatory Medical Care Survey. Am Heart J. 2022 10; 252:60-69.
    View in: PubMed
    Score: 0.492
  12. Guideline-Concordant Statin Therapy Use?in Secondary Prevention: Should the Medical Community Wait for Divine Intervention? J Am Coll Cardiol. 2022 05 10; 79(18):1814-1817.
    View in: PubMed
    Score: 0.490
  13. A Mistake Not to Be Repeated: What Can We Learn from the Underutilization of Statin Therapy for Efficient Dissemination of Cardioprotective Glucose Lowering Agents? Curr Cardiol Rep. 2022 06; 24(6):689-698.
    View in: PubMed
    Score: 0.486
  14. Potential Impact of the 2019 ACC/AHA Guidelines on the Primary Prevention of Cardiovascular Disease Recommendations on the Inappropriate Routine Use of Aspirin and Aspirin Use Without a Recommended Indication for Primary Prevention of Cardiovascular Disease in Cardiology Practices: Insights From the NCDR PINNACLE Registry. Circ Cardiovasc Qual Outcomes. 2022 03; 15(3):e007979.
    View in: PubMed
    Score: 0.481
  15. Association of patient, provider and facility related characteristics with statin associated side effects and statin use: Insight from the Veteran's Affairs healthcare system. J Clin Lipidol. 2021 Nov-Dec; 15(6):832-839.
    View in: PubMed
    Score: 0.470
  16. High-Intensity Statins Benefit High-Risk Patients: Why and How to Do Better. Mayo Clin Proc. 2021 10; 96(10):2660-2670.
    View in: PubMed
    Score: 0.469
  17. Epidemiology and risk factors for stroke in young individuals: implications for prevention. Curr Opin Cardiol. 2021 09 01; 36(5):565-571.
    View in: PubMed
    Score: 0.467
  18. Department of Veterans Affairs (VA) and U.S. Department of Defense (DoD) guidelines for management of dyslipidemia and cardiovascular disease risk reduction: Putting evidence in context. Prog Cardiovasc Dis. 2021 Sep-Oct; 68:2-6.
    View in: PubMed
    Score: 0.465
  19. Statins in COVID-19 infection: A rehash of old themes or truly a new hope? J Clin Lipidol. 2021 May-Jun; 15(3):399-401.
    View in: PubMed
    Score: 0.456
  20. Facility-Level Variation in Reported Statin-Associated Side Effects Among Patients with Atherosclerotic Cardiovascular Disease-Perspective from the Veterans Affair Healthcare System. Cardiovasc Drugs Ther. 2022 04; 36(2):295-300.
    View in: PubMed
    Score: 0.449
  21. Significant Facility-Level Variation in Utilization of and Adherence with Secondary Prevention Therapies Among Patients with Premature Atherosclerotic Cardiovascular Disease: Insights from the VITAL (Veterans wIth premaTure AtheroscLerosis) Registry7. Cardiovasc Drugs Ther. 2022 02; 36(1):93-102.
    View in: PubMed
    Score: 0.447
  22. Shared Decisions: A Qualitative Study on Clinician and Patient Perspectives on Statin Therapy and Statin-Associated Side Effects. J Am Heart Assoc. 2020 11 17; 9(22):e017915.
    View in: PubMed
    Score: 0.442
  23. Real-world data, theoretical application of guidelines, cost, and access: how do we optimize non-statin therapy for LDL-C/non-HDL-C/ApoB? Eur Heart J. 2020 10 21; 41(40):3910-3912.
    View in: PubMed
    Score: 0.440
  24. Statin Prescription Rates, Adherence, and Associated Clinical Outcomes Among Women with PAD and ICVD. Cardiovasc Drugs Ther. 2020 12; 34(6):745-754.
    View in: PubMed
    Score: 0.436
  25. Evaluation of Aspirin and Statin Therapy Use and Adherence in Patients With Premature Atherosclerotic Cardiovascular Disease. JAMA Netw Open. 2020 08 03; 3(8):e2011051.
    View in: PubMed
    Score: 0.434
  26. Coronary Artery Calcification, Statin Use and Long-Term Risk of Atherosclerotic Cardiovascular Disease Events (from the Multi-Ethnic Study of Atherosclerosis). Am J Cardiol. 2020 03 15; 125(6):835-839.
    View in: PubMed
    Score: 0.416
  27. Association between frequency of primary care provider visits and evidence-based statin prescribing and statin adherence: Findings from the Veterans Affairs system. Am Heart J. 2020 03; 221:9-18.
    View in: PubMed
    Score: 0.414
  28. The use of structured data elements to identify ASCVD patients with statin-associated side effects: Insights from the Department of Veterans Affairs. J Clin Lipidol. 2019 Sep - Oct; 13(5):797-803.e1.
    View in: PubMed
    Score: 0.405
  29. Relation Between Cardiology Follow-Up Visits, Evidence-Based Statin Prescribing, and Statin Adherence (from the Veterans Affairs Health Care System). Am J Cardiol. 2019 10 15; 124(8):1165-1170.
    View in: PubMed
    Score: 0.404
  30. Association Between Lipid Testing and Statin Adherence in the Veterans Affairs Health System. Am J Med. 2019 09; 132(9):e693-e700.
    View in: PubMed
    Score: 0.399
  31. CLEAR Serenity Trial: More Clarity for the Future of Bempedoic Acid in Patients Unable to Take Statins? J Am Heart Assoc. 2019 04 02; 8(7):e012352.
    View in: PubMed
    Score: 0.395
  32. Association of Body Mass Index With Risk Factor Optimization and Guideline-Directed Medical Therapy in US Veterans With Cardiovascular Disease. Circ Cardiovasc Qual Outcomes. 2019 01; 12(1):e004817.
    View in: PubMed
    Score: 0.389
  33. Making prescriptions "talk" to stroke and heart attack survivors to improve adherence: Results of a randomized clinical trial (The Talking Rx Study). PLoS One. 2018; 13(12):e0197671.
    View in: PubMed
    Score: 0.388
  34. Lipid-Lowering Therapies: Risks in Women and Evidence-Based Options. Tex Heart Inst J. 2018 08; 45(4):238-239.
    View in: PubMed
    Score: 0.377
  35. Variation in Lipid-Lowering Therapy Use in Patients With Low-Density Lipoprotein Cholesterol =190 mg/dL: Insights From the National Cardiovascular Data Registry-Practice Innovation and Clinical Excellence Registry. Circ Cardiovasc Qual Outcomes. 2018 05; 11(5):e004652.
    View in: PubMed
    Score: 0.371
  36. Statin prescription rates and their facility-level variation in patients with peripheral artery disease and ischemic cerebrovascular disease: Insights from the Department of Veterans Affairs. Vasc Med. 2018 06; 23(3):232-240.
    View in: PubMed
    Score: 0.369
  37. Adoption of the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guideline in Cardiology Practices Nationwide. JAMA Cardiol. 2017 04 01; 2(4):361-369.
    View in: PubMed
    Score: 0.344
  38. Practice-Level Variation in?Statin Use Among Patients With Diabetes: Insights From the PINNACLE Registry. J Am Coll Cardiol. 2016 09 20; 68(12):1368-9.
    View in: PubMed
    Score: 0.332
  39. Risk Factor Optimization and Guideline-Directed Medical Therapy in US Veterans With Peripheral Arterial and Ischemic Cerebrovascular Disease Compared to Veterans With Coronary Heart Disease. Am J Cardiol. 2016 Oct 15; 118(8):1144-1149.
    View in: PubMed
    Score: 0.328
  40. Statin Use and Its Facility-Level Variation in Patients With Diabetes: Insight From the Veterans Affairs National Database. Clin Cardiol. 2016 Apr; 39(4):185-91.
    View in: PubMed
    Score: 0.321
  41. Using a tailored health information technology- driven intervention to improve health literacy and medication adherence in a Pakistani population with vascular disease (Talking Rx) - study protocol for a randomized controlled trial. Trials. 2016 Mar 05; 17(1):121.
    View in: PubMed
    Score: 0.319
  42. Case-based educational intervention to assess change in providers' knowledge and attitudes towards the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guideline. Atherosclerosis. 2016 Mar; 246:115-20.
    View in: PubMed
    Score: 0.316
  43. Implications for Ezetimibe Therapy Use Based on IMPROVE-IT Criteria. Am J Med. 2015 Nov; 128(11):1253-6.
    View in: PubMed
    Score: 0.304
  44. Coronary artery disease performance measures and statin use in patients with recent percutaneous coronary intervention or recent coronary artery bypass grafting (from the NCDR PINNACLE registry). Am J Cardiol. 2015 Apr 15; 115(8):1013-8.
    View in: PubMed
    Score: 0.296
  45. Is high-intensity statin therapy associated with lower statin adherence compared with low- to moderate-intensity statin therapy? Implications of the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guidelines. Clin Cardiol. 2014 Nov; 37(11):653-9.
    View in: PubMed
    Score: 0.290
  46. Gender disparities in evidence-based statin therapy in patients with cardiovascular disease. Am J Cardiol. 2015 Jan 01; 115(1):21-6.
    View in: PubMed
    Score: 0.290
  47. Statins in the primary and secondary prevention of cardiovascular disease in women: facts and myths. Tex Heart Inst J. 2013; 40(3):288-9.
    View in: PubMed
    Score: 0.256
  48. Association between statins and infections after coronary artery bypass grafting. Int J Cardiol. 2013 Sep 20; 168(1):117-20.
    View in: PubMed
    Score: 0.252
  49. Preoperative statin therapy decreases risk of postoperative renal insufficiency. Cardiovasc Ther. 2010 Apr; 28(2):80-6.
    View in: PubMed
    Score: 0.212
  50. Does preoperative statin therapy improve outcomes in patients undergoing isolated cardiac valve surgery? Am J Cardiol. 2008 Nov 01; 102(9):1235-9.
    View in: PubMed
    Score: 0.190
  51. Preoperative statin therapy is not associated with a decrease in the incidence of postoperative atrial fibrillation in patients undergoing cardiac surgery. Am Heart J. 2008 Mar; 155(3):541-6.
    View in: PubMed
    Score: 0.181
  52. Long-Term Mortality in Patients With Severe Hypercholesterolemia Phenotype From a Racial and Ethnically Diverse US Cohort. Circulation. 2024 02 06; 149(6):417-426.
    View in: PubMed
    Score: 0.136
  53. Novel therapies to achieve the recommended low-density lipoprotein cholesterol concentration (LDL-C) targets for patients after coronary artery bypass grafting. J Thorac Cardiovasc Surg. 2024 02; 167(2):723-730.e4.
    View in: PubMed
    Score: 0.132
  54. Burden and predictors of statin use in primary and secondary prevention of atherosclerotic vascular disease in the US: from the National Health and Nutrition Examination Survey 2017-2020. Eur J Prev Cardiol. 2022 10 20; 29(14):1830-1838.
    View in: PubMed
    Score: 0.126
  55. A stepwise approach to prescribing novel lipid-lowering medications. J Clin Lipidol. 2022 Nov-Dec; 16(6):822-832.
    View in: PubMed
    Score: 0.126
  56. Lipid-Lowering Therapy Use and Intensification Among United States Veterans Following Myocardial Infarction or Coronary Revascularization Between 2015 and 2019. Circ Cardiovasc Qual Outcomes. 2022 12; 15(12):e008861.
    View in: PubMed
    Score: 0.126
  57. World Heart Federation Cholesterol Roadmap 2022. Glob Heart. 2022; 17(1):75.
    View in: PubMed
    Score: 0.126
  58. Adherence to lipid monitoring and its impact on treat intensification of LDL-C lowering therapies at an urban academic medical center. J Clin Lipidol. 2022 Jul-Aug; 16(4):491-497.
    View in: PubMed
    Score: 0.123
  59. Variation in statin prescription among veterans with HIV and known atherosclerotic cardiovascular disease. Am Heart J. 2022 07; 249:12-22.
    View in: PubMed
    Score: 0.121
  60. Efficacy and safety for the achievement of guideline-recommended lower low-density lipoprotein cholesterol levels: a systematic review and meta-analysis. Eur J Prev Cardiol. 2022 02 09; 28(18):2001-2009.
    View in: PubMed
    Score: 0.120
  61. Association of Low-Density Lipoprotein Testing After an Atherosclerotic Cardiovascular Event with Subsequent Statin Adherence and Intensification. Am J Med. 2022 05; 135(5):603-606.
    View in: PubMed
    Score: 0.119
  62. Assessment of Coronary Artery Calcium Scoring to Guide Statin Therapy Allocation According to Risk-Enhancing Factors: The Multi-Ethnic Study of Atherosclerosis. JAMA Cardiol. 2021 10 01; 6(10):1161-1170.
    View in: PubMed
    Score: 0.118
  63. Cardiovascular Disease Risk-Based Statin Utilization and Associated Outcomes in a Primary Prevention Cohort: Insights From a Large Health Care Network. Circ Cardiovasc Qual Outcomes. 2021 09; 14(9):e007485.
    View in: PubMed
    Score: 0.117
  64. 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2021 08 31; 78(9):960-993.
    View in: PubMed
    Score: 0.116
  65. Lipid Monitoring After Initiation of Lipid-Lowering Therapies: Return of Performance Measures? Curr Cardiol Rep. 2021 07 16; 23(9):116.
    View in: PubMed
    Score: 0.116
  66. Sex-Related Disparities in Cardiovascular Health Care Among Patients With Premature Atherosclerotic Cardiovascular Disease. JAMA Cardiol. 2021 07 01; 6(7):782-790.
    View in: PubMed
    Score: 0.115
  67. Gender Differences in Premature Coronary Artery Disease (from the National Data from the NHANES Database). Am J Cardiol. 2021 08 15; 153:142-144.
    View in: PubMed
    Score: 0.115
  68. How low is safe? The frontier of very low (<30 mg/dL) LDL cholesterol. Eur Heart J. 2021 06 07; 42(22):2154-2169.
    View in: PubMed
    Score: 0.115
  69. Patient perceptions and use of non-statin lipid lowering therapy among patients with or at risk for atherosclerotic cardiovascular disease: Insights from the PALM registry. Clin Cardiol. 2021 Jun; 44(6):863-870.
    View in: PubMed
    Score: 0.115
  70. Transatlantic guidelines on dyslipidemia and cardiovascular risk: key differences across the pond. Curr Opin Endocrinol Diabetes Obes. 2021 04 01; 28(2):114-121.
    View in: PubMed
    Score: 0.114
  71. Triglycerides and ASCVD Risk Reduction: Recent Insights and Future Directions. Curr Atheroscler Rep. 2020 06 03; 22(7):25.
    View in: PubMed
    Score: 0.107
  72. Beliefs, risk perceptions, and lipid management among patients with and without diabetes: Results from the PALM registry. Am Heart J. 2020 07; 225:88-96.
    View in: PubMed
    Score: 0.107
  73. Association between intensity of statin therapy and mortality in persons with chronic kidney disease. Nephrol Dial Transplant. 2020 02 01; 35(2):312-319.
    View in: PubMed
    Score: 0.105
  74. Impact of Lipid Monitoring on Treatment Intensification of Cholesterol Lowering Therapies (from the Veterans Affairs Healthcare System). Am J Cardiol. 2020 03 15; 125(6):874-879.
    View in: PubMed
    Score: 0.104
  75. Association Between Poverty and Appropriate Statin Prescription for the Treatment of Hyperlipidemia in the United States: An Analysis From the ACC NCDR PINNACLE Registry. Cardiovasc Revasc Med. 2020 08; 21(8):1016-1021.
    View in: PubMed
    Score: 0.104
  76. Intensity of Lipid Lowering With Statin Therapy in Patients With Cerebrovascular Disease Versus Coronary Artery Disease: Insights from the PALM Registry. J Am Heart Assoc. 2019 10; 8(19):e013229.
    View in: PubMed
    Score: 0.102
  77. Sex Differences in the Use of Statins in Community Practice. Circ Cardiovasc Qual Outcomes. 2019 08; 12(8):e005562.
    View in: PubMed
    Score: 0.101
  78. Very High-Risk ASCVD and Eligibility for Nonstatin Therapies Based on the 2018?AHA/ACC Cholesterol Guidelines. J Am Coll Cardiol. 2019 08 06; 74(5):712-714.
    View in: PubMed
    Score: 0.101
  79. Major Randomized Clinical Trials in Cardiovascular Disease Prevention Presented at the 2019 American College of Cardiology Annual Scientific Session. Curr Atheroscler Rep. 2019 05 24; 21(8):31.
    View in: PubMed
    Score: 0.100
  80. Practice-level variation in statin use and low-density lipoprotein cholesterol control in the United States: Results from the Patient and Provider Assessment of Lipid Management (PALM) registry. Am Heart J. 2019 08; 214:113-124.
    View in: PubMed
    Score: 0.100
  81. Four Cases of Cholesterol Management Informed by the 2018 American Heart Association/American College of Cardiology Multisociety Guideline on the Management of Blood Cholesterol. JAMA Cardiol. 2019 05 01; 4(5):473-477.
    View in: PubMed
    Score: 0.099
  82. Patient-Reported Reasons for Declining or Discontinuing Statin Therapy: Insights From the PALM Registry. J Am Heart Assoc. 2019 04 02; 8(7):e011765.
    View in: PubMed
    Score: 0.099
  83. The 2018 Cholesterol Management Guidelines: Topics in Secondary ASCVD Prevention Clinicians Need to Know. Curr Atheroscler Rep. 2019 04 02; 21(6):20.
    View in: PubMed
    Score: 0.099
  84. 2018 Cholesterol Guidelines: Key Topics in Primary Prevention. Curr Atheroscler Rep. 2019 03 16; 21(5):17.
    View in: PubMed
    Score: 0.099
  85. Association of Statin Adherence With Mortality in Patients With Atherosclerotic Cardiovascular Disease. JAMA Cardiol. 2019 03 01; 4(3):206-213.
    View in: PubMed
    Score: 0.098
  86. Omega-3 Fatty Acid and Cardiovascular Outcomes: Insights From Recent Clinical Trials. Curr Atheroscler Rep. 2019 01 10; 21(1):1.
    View in: PubMed
    Score: 0.097
  87. Association of Clinician Knowledge and Statin Beliefs With Statin Therapy Use and Lipid Levels (A Survey of US Practice in the PALM Registry). Am J Cardiol. 2019 04 01; 123(7):1011-1018.
    View in: PubMed
    Score: 0.097
  88. Influence of Cardiovascular Risk Communication Tools and Presentation Formats on Patient Perceptions and Preferences. JAMA Cardiol. 2018 12 01; 3(12):1192-1199.
    View in: PubMed
    Score: 0.097
  89. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task?Force?on?Clinical Practice Guidelines. J Am Coll Cardiol. 2019 06 25; 73(24):3168-3209.
    View in: PubMed
    Score: 0.096
  90. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task?Force?on?Clinical Practice Guidelines. J Am Coll Cardiol. 2019 06 25; 73(24):e285-e350.
    View in: PubMed
    Score: 0.096
  91. Use of Risk Assessment Tools to Guide Decision-Making in the Primary Prevention of Atherosclerotic Cardiovascular Disease: A Special Report From the American Heart Association and American College of Cardiology. Circulation. 2019 06 18; 139(25):e1162-e1177.
    View in: PubMed
    Score: 0.096
  92. Measurement of Low-Density Lipoprotein Cholesterol Levels in Primary and Secondary Prevention Patients: Insights From the PALM Registry. J Am Heart Assoc. 2018 09 18; 7(18):e009251.
    View in: PubMed
    Score: 0.095
  93. Association of Patient Perceptions of Cardiovascular Risk and Beliefs on Statin Drugs With Racial Differences in Statin Use: Insights From the Patient and Provider Assessment of Lipid Management Registry. JAMA Cardiol. 2018 08 01; 3(8):739-748.
    View in: PubMed
    Score: 0.094
  94. Statin Eligibility, Coronary Artery Calcium, and Subsequent Cardiovascular Events According to the 2016 United States Preventive Services Task Force (USPSTF) Statin Guidelines: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Heart Assoc. 2018 06 13; 7(12).
    View in: PubMed
    Score: 0.093
  95. Frequency of Statin Use in Patients With Low-Density Lipoprotein Cholesterol =190 mg/dl from the Veterans Affairs Health System. Am J Cardiol. 2018 09 01; 122(5):756-761.
    View in: PubMed
    Score: 0.093
  96. Statin Use and Adverse Effects Among Adults >75?Years of Age: Insights From the Patient and Provider Assessment of Lipid Management (PALM) Registry. J Am Heart Assoc. 2018 05 08; 7(10).
    View in: PubMed
    Score: 0.093
  97. Prevalence and Management of Symptoms Associated With Statin Therapy in Community Practice: Insights From the PALM (Patient and Provider Assessment of Lipid Management) Registry. Circ Cardiovasc Qual Outcomes. 2018 03; 11(3):e004249.
    View in: PubMed
    Score: 0.092
  98. Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers: Insights Derived From the FOURIER Trial. JAMA Cardiol. 2017 12 01; 2(12):1369-1374.
    View in: PubMed
    Score: 0.090
  99. Association Between Intensity of Statin Therapy and Mortality in Patients With Atherosclerotic Cardiovascular Disease. JAMA Cardiol. 2017 01 01; 2(1):47-54.
    View in: PubMed
    Score: 0.085
  100. National Trends in Statin Use and Expenditures in the US Adult Population From 2002 to 2013: Insights From the Medical Expenditure Panel Survey. JAMA Cardiol. 2017 01 01; 2(1):56-65.
    View in: PubMed
    Score: 0.085
  101. Harder-to-Treat Patients: Recognizing Them and Adapting Treatment Strategies. Am J Cardiol. 2016 Sep 15; 118(6 Suppl):13A-8A.
    View in: PubMed
    Score: 0.083
  102. Comparative effectiveness of outpatient cardiovascular disease and diabetes care delivery between advanced practice providers and physician providers in primary care: Implications for care under the Affordable Care Act. Am Heart J. 2016 Nov; 181:74-82.
    View in: PubMed
    Score: 0.083
  103. Lipid Management Guidelines from the Departments of Veteran Affairs and Defense: A?Critique. Am J Med. 2016 09; 129(9):906-12.
    View in: PubMed
    Score: 0.081
  104. Efficacy of Angiotensin-Converting Enzyme Inhibitors and Angiotensin-Receptor Blockers in Coronary Artery Disease without Heart Failure in the Modern Statin Era: a Meta-Analysis of Randomized-Controlled Trials. Cardiovasc Drugs Ther. 2016 Apr; 30(2):189-98.
    View in: PubMed
    Score: 0.080
  105. Differential Lipid Response to Statins Is Associated With Variants in the BUD13-APOA5 Gene Region. J Cardiovasc Pharmacol. 2015 Aug; 66(2):183-8.
    View in: PubMed
    Score: 0.077
  106. Eligibility for statin therapy according to new cholesterol guidelines and prevalent use of medication to lower lipid levels in an older US Cohort: the Atherosclerosis Risk in Communities Study Cohort. JAMA Intern Med. 2015 Jan; 175(1):138-40.
    View in: PubMed
    Score: 0.074
  107. Implications of the 2013 ACC/AHA cholesterol guidelines for adults in contemporary cardiovascular practice: insights from the NCDR PINNACLE registry. J Am Coll Cardiol. 2014 Dec 02; 64(21):2183-92.
    View in: PubMed
    Score: 0.073
  108. Dyslipidemia, coronary artery calcium, and incident atherosclerotic cardiovascular disease: implications for statin therapy from the multi-ethnic study of atherosclerosis. Circulation. 2014 Jan 07; 129(1):77-86.
    View in: PubMed
    Score: 0.068
  109. LPL gene variants affect apoC-III response to combination therapy of statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia. J Lipid Res. 2012 Mar; 53(3):556-560.
    View in: PubMed
    Score: 0.060
  110. Barriers to non-HDL cholesterol goal attainment by providers. Am J Med. 2011 Sep; 124(9):876-80.e2.
    View in: PubMed
    Score: 0.058
  111. Variants in the APOA5 gene region and the response to combination therapy with statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia. Atherosclerosis. 2011 Dec; 219(2):737-42.
    View in: PubMed
    Score: 0.058
  112. Relationship between circulating levels of RANTES (regulated on activation, normal T-cell expressed, and secreted) and carotid plaque characteristics: the Atherosclerosis Risk in Communities (ARIC) Carotid MRI Study. Eur Heart J. 2011 Feb; 32(4):459-68.
    View in: PubMed
    Score: 0.055
  113. Therapy and clinical trials: HDL-cholesterol and niacin therapy--past, present, and future. Curr Opin Lipidol. 2010 Apr; 21(2):165-6.
    View in: PubMed
    Score: 0.053
  114. Lipid management: considerations in acute coronary syndrome. Curr Cardiol Rep. 2008 Jul; 10(4):334-41.
    View in: PubMed
    Score: 0.047
  115. The role of lipoprotein-associated phospholipase A2 as a marker for atherosclerosis. Curr Atheroscler Rep. 2007 Aug; 9(2):97-103.
    View in: PubMed
    Score: 0.044
  116. Patient-Perceived Versus Actual Risk of Cardiovascular Disease and Associated Willingness to Consider and Use Prevention Therapy. Circ Cardiovasc Qual Outcomes. 2021 01; 14(1):e006548.
    View in: PubMed
    Score: 0.028
  117. Novel emerging therapies in atherosclerosis targeting lipid metabolism. Expert Opin Investig Drugs. 2020 Jun; 29(6):611-622.
    View in: PubMed
    Score: 0.027
  118. Medical Therapy Utilization and Long-Term Outcomes Following Percutaneous Coronary Intervention: Five-Year Results From the Veterans Affairs Clinical Assessment, Reporting, and Tracking System Program. Circ Cardiovasc Qual Outcomes. 2019 11; 12(11):e005455.
    View in: PubMed
    Score: 0.026
  119. Primary and Secondary Prevention of Cardiovascular Disease in Patients with Chronic Kidney Disease. Curr Atheroscler Rep. 2019 06 22; 21(9):32.
    View in: PubMed
    Score: 0.025
  120. ApoB, small-dense LDL-C, Lp(a), LpPLA2 activity, and cognitive change. Neurology. 2019 05 28; 92(22):e2580-e2593.
    View in: PubMed
    Score: 0.025
  121. National Trends in Nonstatin Use and Expenditures Among the US Adult Population From 2002 to 2013: Insights From Medical Expenditure Panel?Survey. J Am Heart Assoc. 2018 01 22; 7(2).
    View in: PubMed
    Score: 0.023
  122. Clinical pharmacist understanding of the 2013 American College of Cardiology/American Heart Association cholesterol guideline. J Clin Lipidol. 2018 Mar - Apr; 12(2):367-374.e3.
    View in: PubMed
    Score: 0.023
  123. Patient-Provider Communication and Health Outcomes Among Individuals With Atherosclerotic Cardiovascular Disease in the United States: Medical Expenditure Panel Survey 2010 to 2013. Circ Cardiovasc Qual Outcomes. 2017 04; 10(4).
    View in: PubMed
    Score: 0.022
  124. Frequency of Attainment of Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol Goals in Cardiovascular Clinical Practice (from the National Cardiovascular Data Registry PINNACLE Registry). Am J Cardiol. 2015 Aug 15; 116(4):547-53.
    View in: PubMed
    Score: 0.019
  125. Rare LPL gene variants attenuate triglyceride reduction and HDL cholesterol increase in response to fenofibric acid therapy in individuals with mixed dyslipidemia. Atherosclerosis. 2014 Jun; 234(2):249-53.
    View in: PubMed
    Score: 0.017
  126. Variability and persistence of aspirin response in lower extremity peripheral arterial disease patients. J Vasc Surg. 2011 Mar; 53(3):668-75.
    View in: PubMed
    Score: 0.014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.